Department of Ophthalmology, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey.
Eur Neurol. 2012;68(1):20-2. doi: 10.1159/000337615. Epub 2012 Jun 5.
The aim of the study was to determine the intraocular pressure (IOP) changes with high-dose intravenous methylprednisolone (HIVMP) treatment given for the treatment of acute relapses in relapsing multiple sclerosis (MS).
Forty patients with clinically definite MS admitted for a new demyelinating event were included in the study. All patients were treated with HIVMP (1 g) once daily for 5 consecutive days. IOPs of 40 patients were recorded before treatment, during the course of systemic methylprednisolone administration and at the end of each month for 3 successive months, four times a day. The average IOP of each day was statistically compared to the pretreatment value.
The initial IOP was 13.5 ± 2.4 mm Hg before steroid administration. The IOP values tended to rise significantly during intravenous corticosteroid administration and in the first month of follow-up (p < 0.05). However, the increase remained within normal ranges and IOP values never exceeded 20 mm Hg during the follow-ups.
Our study demonstrated that MS patients treated with HIVMP have increased IOP which does not lead to conditions at risk for developing glaucoma.
本研究旨在确定大剂量静脉注射甲基强的松龙（HIVMP）治疗复发型多发性硬化症（MS）急性发作时的眼压（IOP）变化。
本研究纳入了 40 例因新的脱髓鞘事件入院的临床确诊 MS 患者。所有患者均接受 HIVMP（1g）治疗，每日一次，连续 5 天。记录 40 例患者治疗前、全身甲基强的松龙给药期间和随后 3 个月每月末的 IOP，每日 4 次。对每天的平均 IOP 与治疗前值进行统计学比较。
在给予类固醇之前，初始 IOP 为 13.5 ± 2.4mmHg。在静脉内皮质类固醇治疗期间和随访的第一个月，IOP 值明显升高（p<0.05）。然而，增加仍在正常范围内，在随访期间，IOP 值从未超过 20mmHg。
我们的研究表明，接受 HIVMP 治疗的 MS 患者的 IOP 升高，但不会导致发生青光眼的风险增加。
